Submitted:
02 July 2024
Posted:
04 July 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Material and Method
3. Definition and Classification of IE
4. Statistical Methods
5. Results
6. Discussion
References
- Osler, W. Gulstonian lectures on malignant endocarditis. Lecture III. Lancet 1885, 1, 505–508. [Google Scholar] [CrossRef]
- Osler, W. Gulstonian lectures on malignant endocarditis. Lecture II. Lancet 1885, 1, 459–464. [Google Scholar] [CrossRef]
- Hoen, B. Changing Profile of Infective Endocarditis Results of a 1-Year Survey in France. JAMA. 2002, 288, 75. [Google Scholar] [CrossRef]
- Murdoch, D.R.; Corey, G.R.; Hoen, B.; Miro, J.M.; Fowler, V.G., Jr.; Bayer, A.S.; Karchmer, A.W.; Olaison, L.; Pappas, P.A.; Moreillon, P.; et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch. Intern. Med. 2009, 169, 463–473. [Google Scholar] [CrossRef] [PubMed]
- Habib, G.; Erba, P.A.; Iung, B.; Donal, E.; Cosyns, B.; Laroche, C.; Popescu, B.A.; Prendergast, B.; Tornos, P.; Sadeghpour, A.; et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur. Heart J. 2019, 40, 3222–3232. [Google Scholar] [CrossRef]
- Sunder, S.; Grammatico-Guillon, L.; Lemaignen, A.; Lacasse, M.; Gaborit, C.; Boutoille, D.; Tattevin, P.; Denes, E.; Guimard, T.; Dupont, M.; et al. Incidence, characteristics, and mortality of infective endocarditis in France in 2011. PLOS ONE 2019, 14, e0223857. [Google Scholar] [CrossRef] [PubMed]
- Kang DH, Kim YJ, Kim SH, Sun BJ, Kim DH, Yun SC, et al. Early Surgery versus Conventional Treatment for Infective Endocarditis. New England Journal of Medicine. 2012, 366, 2466–2473. [Google Scholar] [CrossRef] [PubMed]
- Lalani, T.; Cabell, C.H.; Benjamin, D.K.; Lasca, O.; Naber, C.; Fowler, V.G.; Corey, G.R.; Chu, V.H.; Fenely, M.; Pachirat, O.; et al. Analysis of the Impact of Early Surgery on In-Hospital Mortality of Native Valve Endocarditis. Circ. 2010, 121, 1005–1013. [Google Scholar] [CrossRef] [PubMed]
- Delgado V, Ajmone Marsan N, De Waha S, Bonaros N, Brida M, Burri H, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023, 44, 3948–4042. [Google Scholar] [CrossRef]
- Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 1987, 40, 373–383. [Google Scholar] [CrossRef]
- Durack, D.T.; Lukes, A.S.; Bright, D.K.; Service, D.E. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am. J. Med. 1994, 96, 200–209. [Google Scholar] [CrossRef] [PubMed]
- Bohbot Y, Habib G, Laroche C, Stöhr E, Chirouze C, Hernandez-Meneses M, et al. Characteristics, management, and outcomes of patients with left-sided infective endocarditis complicated by heart failure: a substudy of the ESC-EORP EURO-ENDO (European infective endocarditis) registry. Eur J Heart Fail. 2022, 24, 1253–1265. [Google Scholar] [CrossRef] [PubMed]
- Hase, R.; Otsuka, Y.; Yoshida, K.; Hosokawa, N. Profile of infective endocarditis at a tertiary-care hospital in Japan over a 14-year period: characteristics, outcome and predictors for in-hospital mortality. Int. J. Infect. Dis. 2015, 33, 62–66. [Google Scholar] [CrossRef] [PubMed]
- Maguire, D.J.; Arora, R.C.; Hiebert, B.M.; Dufault, B.; Thorleifson, M.D. The Epidemiology of Endocarditis in Manitoba: A Retrospective Study. CJC Open 2021, 3, 1471–1481. [Google Scholar] [CrossRef] [PubMed]
- Heredia-Rodríguez, M.; Hernández, A.; Bustamante-Munguira, J.; Álvarez, F.J.; Eiros, J.M.; Castrodeza, J.; Tamayo, E. Evolution of the Incidence, Mortality, and Cost of Infective Endocarditis in Spain Between 1997 and 2014. J. Gen. Intern. Med. 2018, 33, 1610–1613. [Google Scholar] [CrossRef] [PubMed]
- Sousa, C.; Nogueira, P.; Pinto, F.J. Insight into the epidemiology of infective endocarditis in Portugal: a contemporary nationwide study from 2010 to 2018. BMC Cardiovasc. Disord. 2021, 21, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Brink, F.S.v.D.; Swaans, M.J.; Hoogendijk, M.G.; Alipour, A.; Kelder, J.C.; Jaarsma, W.; Eefting, F.D.; Groenmeijer, B.; Kupper, A.J.F.; Berg, J.M.T. Increased incidence of infective endocarditis after the 2009 European Society of Cardiology guideline update: a nationwide study in the Netherlands. Eur. Hear. J. Qual. Care Clin. Outcomes 2016, 3, 141–147. [Google Scholar] [CrossRef]
- Kim, J.H.; Lee, H.J.; Ku, N.S.; Lee, S.H.; Lee, S.; Choi, J.Y.; Yeom, J.-S. Infective endocarditis at a tertiary care hospital in South Korea. Heart 2020, 107, 135–141. [Google Scholar] [CrossRef] [PubMed]
- Arora, N.; Panda, P.K.; Cr, P.; Uppal, L.; Saroch, A.; Angrup, A.; Sharma, N.; Sharma, Y.P.; Vijayvergiya, R.; Rohit, M.K.; et al. Changing spectrum of infective endocarditis in India: An 11-year experience from an academic hospital in North India. Indian Hear. J. 2021, 73, 711–717. [Google Scholar] [CrossRef]
- Noubiap JJ, Nkeck JR, Kwondom BS, Nyaga UF. Epidemiology of infective endocarditis in Africa: a systematic review and meta-analysis. Lancet Glob Health. 2022, 10, e77–86. [Google Scholar] [CrossRef]
- Marques, A.; Cruz, I.; Caldeira, D.; Alegria, S.; Gomes, A.C.; Broa, A.L.; João, I.; Pereira, H. Fatores de Risco para Mortalidade Hospitalar na Endocardite Infecciosa. Arq. Bras. de Cardiol. 2019, 114, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Horder, TJ. Infective endocarditis: with an analysis of 150 cases and with special reference to the chronic form of the disease. Quart J Med 1909, 2, 289–329. [Google Scholar]
- Tornos, P. Infective endocarditis in Europe: lessons from the Euro heart survey. Heart. 2005, 91, 571–575. [Google Scholar] [CrossRef]
- Babeș, E.E.; Lucuța, D.A.; Petcheși, C.D.; Zaha, A.A.; Ilyes, C.; Jurca, A.D.; Vesa, C.M.; Zaha, D.C.; Babeș, V.V. Clinical Features and Outcome of Infective Endocarditis in a University Hospital in Romania. Medicina 2021, 57, 158. [Google Scholar] [CrossRef]
- T. Donova. Прoтезен клапен ендoкардит - терапевтичнo пoведение и изхoд. Българска кардиoлoги. 2005,4:280–5.
- Servy, A.; Valeyrie-Allanore, L.; Alla, F.; Lechiche, C.; Nazeyrollas, P.; Chidiac, C.; Hoen, B.; Chosidow, O.; Duval, X. Prognostic Value of Skin Manifestations of Infective Endocarditis. JAMA Dermatol. 2014, 150, 494–500. [Google Scholar] [CrossRef]
- Urina-Jassir, M.; Jaimes-Reyes, M.A.; Martinez-Vernaza, S.; Quiroga-Vergara, C.; Urina-Triana, M. Clinical, Microbiological, and Imaging Characteristics of Infective Endocarditis in Latin America: A Systematic Review. Int. J. Infect. Dis. 2022, 117, 312–321. [Google Scholar] [CrossRef]
- Poorzand, H.; Hamidi, F.; Sheybani, F.; Ghaderi, F.; Fazlinezhad, A.; Alimi, H.; Bigdelu, L.; Bizhaem, S.K. Infective Endocarditis: Clinical Characteristics and Echocardiographic Findings. Front. Cardiovasc. Med. 2022, 9, 789624. [Google Scholar] [CrossRef] [PubMed]
- Tran, H.M.; Truong, V.T.; Ngo, T.M.N.; Bui, Q.P.V.; Nguyen, H.C.; Le, T.T.Q.; Mazur, W.; Chung, E.; Cafardi, J.M.; Pham, K.P.N.; et al. Microbiological profile and risk factors for in-hospital mortality of infective endocarditis in tertiary care hospitals of south Vietnam. PLOS ONE 2017, 12, e0189421–e0189421. [Google Scholar] [CrossRef] [PubMed]
- Vahabi, A.; Gül, F.; Garakhanova, S.; Sipahi, H.; Sipahi, O.R. Pooled analysis of 1270 infective endocarditis cases in Turkey. J. Infect. Dev. Ctries. 2019, 13, 93–100. [Google Scholar] [CrossRef]
- Tran, H.M.; Truong, V.T.; Ngo, T.M.N.; Bui, Q.P.V.; Nguyen, H.C.; Le, T.T.Q.; Mazur, W.; Chung, E.; Cafardi, J.M.; Pham, K.P.N.; et al. Microbiological profile and risk factors for in-hospital mortality of infective endocarditis in tertiary care hospitals of south Vietnam. PLOS ONE 2017, 12, e0189421–e0189421. [Google Scholar] [CrossRef]
- Seidl, K.; Bayer, A.S.; Fowler, V.G.; McKinnell, J.A.; Hady, W.A.; Sakoulas, G.; Yeaman, M.R.; Xiong, Y.Q. Combinatorial Phenotypic Signatures Distinguish Persistent from Resolving Methicillin-Resistant Staphylococcus aureus Bacteremia Isolates. Antimicrob. Agents Chemother. 2011, 55, 575–582. [Google Scholar] [CrossRef] [PubMed]
- Angstwurm K, Borges AC, Halle E, Schielke E, Weber JR. Neurologische Komplikationen bei infekti ser Endokarditis. Nervenarzt 2004, 75. [Google Scholar]
- Moiseev, V.S.; Kobalava, Z.D.; Pisaryuk, A.S.; Мильтo. .; Kotova, E.O.; Karaulova, Y.L.; Kahktsyan, P.V.; Chukalin, A.S.; Balatskiy, A.V.; Safarova, A.F.; et al. Infective Endocarditis in Moscow General Hospital: Clinical Characteristics and Outcomes (Single-Center 7 Years’ Experience). Kardiologiia 2018, 58, 66–75. [Google Scholar] [CrossRef] [PubMed]
| Variables | 2005 – 2021 G0 n=270 |
2005 – 2015 G1 n-119 |
2016 – 2021 G2 n-151 |
p value |
| Age in yrs., Χ ± SD median (IQR) |
60.86 ±16.83 65 (23) |
58.13 ± 17.71 62.0 (29.0) |
63.01± 15.84 67 (22) |
0.023† |
| Gender – male, n (%) | 177 (65.6) | 79 (66.4) | 98 (64.9) | 0.7968* |
| Тime symptoms-hospita-lization, median (IQR) | 30 (40) | 30 (46) | 30 (40) | 0.932† |
| Previous AB treatment | 142 (52.6) | 59 (49.6) | 82 (54.3) | 0.443* |
| Risk groups, n (%) | ||||
| Low | 136 (50.4) | 55 (46.2) | 81 (53.6) | 0.227* |
| Moderate | 44 (16.3) | 24 (20.2) | 20 (13.2) | 0.122* |
| High | 90 (33.3) | 40 (33.6) | 50 (33.1) | 0.931* |
| Type of valves, n (%) | ||||
| Native IE | 180 (66.7) | 77 (64.7) | 103 (68.2) | 0.629* |
| Prosthetic IE | 88 (32.6) | 41 (34.4) | 47 (31.1) | 0.567* |
| Late prosthetic | 9 (3.3) | 6 (5.0) | 3 (2.0) | 0.172* |
| Early prosthetic | 79 (29.3) | 35 (29.4) | 44 (29.1) | 0.957* |
| CDRIE | 2 (0.7) | 1 (0.8) | 1 (0.7) | 0.061* |
| Entry door, n (%) | ||||
| Unknown | 125 (46.3) | 57 (47.9) | 68 (45) | 0.635* |
| Manipulation/ procedures |
44 (16.3) | 15 (12.6) | 29 (19.2) | 0.145* |
| Dental | 30 (11.1) | 14 (11.8) | 16 (10.6) | 0.756* |
| I.v. drug users | 24 (8.9) | 13 (10.9) | 11 (7.3) | 0.302* |
| Hemodialysis | 13 (4.8) | 3 (2.5) | 10 (6.6) | 0.117* |
| Skin | 10 (3.7) | 2 (1.7) | 8 (5.3) | 0.120* |
| Urogenital | 9 (3.3) | 3 (2.5) | 6 (4.0) | 0.496* |
| Gastrointestinal | 5 (1.9) | 5 (4.2) | 0 (0) | 0.011* |
| Respirators | 5 (1.9) | 5 (4.2) | 0 (0) | 0.011* |
| Ear Nose Throat | 4 (1.5) | 2 (1.7) | 2 (1.3) | 0.787* |
| Others | 1 (0.4) | (0) | 1 (0.7) | 0.361* |
| Predisposing heart conditions, n (%) | ||||
| Prosthetic valve | 76 (28.2) | 33 (27.7) | 43 (28.5) | 0.899* |
| Past IE | 20 (7.4) | 10 (8.4) | 10 (6.6) | 0.575* |
| Past IE prosthetic | 14 (5.2) | 7 (5.9) | 7(4.6) | 0.632* |
| Past IE native valves | 6 (2.2) | 3 (2.5) | 3 (2.0) | 0.782* |
| Rheumatic heart disease | 11 (4.0) | 7 (5.9) | 4 (2.6) | 0.172* |
| Congenital heart disease | 2 (0.7) | 1(0.8) | 1 (0.7) | 0.924* |
| Degenerative valve | 19 (7.0) | 8 (6.7) | 11 (7.3) | 0.848* |
| Bicuspid Ao valve | 11 (4.1) | 5 (4.2) | 6 (4.0) | 0.934* |
| Mitral valve prolapse | 8 (3.0) | 4 (3.4) | 4 (2.6) | 0.734* |
| Without | 123 (45.6) | 51 (42.9) | 72 (47.7) | 0.432* |
| Type of acquisition | ||||
| Community acquired IE | 173 (64.1) | 75 (63.0) | 98 (64.9) | 0.747* |
| Health care–associated IE | 72 (26.7) | 29 (24.4) | 43 (28.5) | 0.350* |
| Intravenous drug use–related IE | 25 (9.3) | 15 (12.6) | 10 (6.6) | 0.091* |
| Variables | 2005 – 2021 G0 n=270 |
2005 – 2015 G1 n-119 |
2016 – 2021 G2 n-151 |
p value |
| Comorbidity | ||||
| CCI, median (IQR) | 3 (3) | 3 (3) | 4 (4) | 0.000† |
| AH | 171 (63.3) | 69 (58.0) | 102 (67.5) | 0.108* |
| CHF | 124 (45.9) | 61 (51.3) | 63 (41.7) | 0.279* |
| Heart surgery | 95 (35.2) | 43 (36.1) | 52 (34.4) | 0.772* |
| CKD | 70 (25.9) | 15 (12.6) | 55 (36.9) | 0.001* |
| CAD | 64 (23.7) | 20 (16.8) | 44 (29.1) | 0.018* |
| Diabetes | 51 (18.9) | 19 (16.0) | 32 (21.2) | 0.279* |
| Atrial fibrillation | 49 (18.1) | 13 (10.9) | 36 (23.8) | 0.006* |
| Past stroke | 40 (14.8) | 16 (13.4) | 24 (15.9) | 0.566* |
| Gastrointestinal | 32 (11.1) | 13 (10.9) | 19 (12.6) | 0.668* |
| Malignancy | 30 (11.1) | 11 (9.2) | 19 (12.6) | 0.377* |
| COPD | 21 (7.8) | 6 (15.0) | 15 (10.0) | 0.213* |
| Hemodialysis | 14 (5.2) | 3 (2.5) | 11 (7.3) | 0.077* |
| Chronic liver disease | 13 (4.8) | 7 (5.9) | 6 (4.0) | 0.470* |
| Systemic disease | 4 (1.5) | 1 (0.8) | 3 (2.0) | 0.416* |
| Clinical symptoms | ||||
| Fever | 263 (97.4) | 115 (96.6) | 148 (98) | 0.474* |
| Anemia | 248 (92.5) | 104 (88.9) | 144 (95.4) | 0.044* |
| Cardiac murmur | 178 (66.2) | 77 (64.7) | 101 (67.3) | 0.654* |
| Splenomegaly | 49 (18.1) | 25 (21.0) | 24 (15.9) | 0.280* |
| Skin disorders | 14 (5.5) | 9 (7.6) | 5 (3.3) | 0.114* |
| Complications | ||||
| Outcome 30 days- died, n (%) |
67 (24.8) | 30 (25.2) | 37 (24.5) | 0.895* |
| Early surgery, n (%) | 54 (20.0) | 20 (16.8) | 34 (22.5) | 0.245* |
| AHF | 128 (47.5) | 58 (48.7) | 70 (46.4) | 0.707* |
| Septic shock | 23 (8.5) | 11 (9.2) | 12 (7.9) | 0.703* |
| Strock | 30 (11.1) | 11 (9.2) | 19 (12.6) | 0.377* |
| Embolism | 56 (20.7) | 24 (21.0) | 31 (20.5) | 0.920* |
| Brain | 29 (51.7) | 11 (45.8) | 18 (58) | 0.369* |
| Lang | 5 (8.9) | 0 (0.0) | 5 (16.1) | - |
| Spleen | 10 (17.9) | 4 (16.7) | 6 (19.4) | 0.800* |
| Skin | 7 (12.5) | 6 (25) | 1 (3.22) | 0.016* |
| Musculoskeletal | 2 (3.57) | 2 (8.3) | 0 (0.0) | - |
| Combine | 3 (5.4) | 2 (8.3) | 1 (3.2) | 0.408* |
| Worsening kidney function | 111 (41.1) | 43 (36.1) | 68 (45.0) | 0.140* |
| Variables | 2005 – 2021 G0 n=270 |
2005 – 2015 G1 n-119 |
2016 – 2021 G2 n-151 |
p value |
| TTE | 270 (100) | 119 (100) | 151(100) | N/A |
| ТТЕ + ТOЕ | 97 (35.9) | 42 (35.3) | 55 (36.4) | 0.8516* |
| Valve location, n (%) | ||||
| АV | 121 (44.8) | 55 (46.2) | 66 (43.7) | 0.682* |
| MV | 74 (27.4) | 29 (24.4) | 45 (29.8) | 0.323* |
| TV | 26 (9.6) | 11 (9.2) | 15 (9.9) | 0.846* |
| PV | 1 (0.4) | 0 (0.0) | 1 (0.7) | 0.361* |
| Bivalve IE | 45 (16.7) | 23 (19.3) | 22 (14.6) | 0.304* |
| АV - MV | 37 (13.7) | 20 (16.8) | 17 (11.3) | 0.192* |
| АV - TV | 4 (1.5) | 1 (0.8) | 3 (2.0) | 0.416* |
| MV - TV | 4 (1.5) | 2 (1.7) | 2 (1.3) | 0.787* |
| CDRIE | 2 (0.74) | 1 (0.8) | 1 (0.66) | 0.693* |
| Vegetations, n (%) | 226 (83.7) | 95 (79.8) | 131 (86.8) | 0.122* |
| < 10 mm | 153 (56.7) | 77 (64.7) | 76 (50.3) | 0.018* |
| 10-15 mm | 38 (14.1) | 7 (5.9) | 31 (20.5) | 0.001* |
| > 15 mm | 35 (13.0) | 11 (9.2) | 24 (15.9) | 0.104* |
| Perivalvular abscess, n (%) | 8 (3.0) | 3 (2.5) | 5 (3.3) | 0.670* |
| Chordal rupture, n (%) | 5 (3.3) | 1 (0.7) | 4 (2.6) | 0.239* |
| EF %. медиана (IQR) | 60 (14) | 63 (14) | 59 (15) | 0.000Ϯ |
| Valve obstruction, n (%) | 32 (11.9) | 13 (10.9) | 19 (12.6) | 0.668* |
| Aortic regurgitation, n (%) | 146 (54) | 66 (60.0) | 80 (53.0) | 0.250* |
| Mild - moderate | 79 (29.3) | 32 (26.8) | 44 (29.2) | 0.663* |
| Severe | 67 (24.8) | 34 (28.5) | 36 (23.9) | 0.392* |
| Mitral regurgitation, n (%) | 115 (42.6) | 52 (43.7) | 63 (41.7) | 0.775* |
| Mild - moderate | 64 (23.7) | 29 (24.3) | 35 (23.2) | 0.833* |
| Severe | 51 (18.9) | 23 (19.3) | 28 (18.5) | 0.868* |
| Tricuspid regurgitation, n (%) | 36 (13.3) | 14 (11.8) | 22 (14.6) | 0.502* |
| Mild - moderate | 16 (6.0) | 6 (5.0) | 10 (6.6) | 0.579* |
| Severe | 20 (7.4) | 8 (6.8) | 12 (7.9) | 0.732* |
| Microbiological agent n (%) |
2005 – 2021 G0 n=270 |
2005 – 2015 G1 n-119 |
2016 – 2021 G2 n-151 |
p-value* |
| Negative hemoculture | 111 (41.1) | 48 (40.3) | 63 (41.8) | 0.803 |
| Staphylococci | 89 (33.0) | 39 (32.8) | 50 (33.1) | 0.958 |
| Staphylococcus aureus | 44 (16.3) | 16 (13.5) | 28 (18.5) | 0.269 |
| Staphylococcus CoNS | 45 (16.7) | 23 (19.3) | 22 (14,6) | 0.303 |
| Streptococci | 21 (7.7) | 12 (10.1) | 9 (6.0) | 0.212 |
| Streptococcus viridans | 9 (3.4) | 6 (5.0) | 3 (2.1) | 0.190 |
| Streptococcus beta-hemolyticus | 2 (0.7) | 0 (0.0) | 2 (1.3) | 0.212 |
| Streptococcus alfa hemolyticus | 6 (2.2) | 2 (1.7) | 4 (2.6) | 0.617 |
| Streptococci -други | 4 (1.5) | 4 (3.4) | 0 (0.0) | 0.022 |
| Enterococci | 25 (9.3) | 9 (7.6) | 16 (10.5) | 0.413 |
| Enterococcus species | 1 (0.4) | 0 (0.0) | 1 (0.65) | 0.378 |
| Enterococus faecalis | 23 (8.5) | 9 (7.6) | 14 (9.2) | 0.639 |
| Enterococcus durans | 1 (0.4) | 0 (0.0) | 1 (0.65) | 0.378 |
| Gram negative (non HASEK) | 19 (7.0) | 8 (6.7) | 11 (7.3) | 0.848 |
| Pseudomonas aeruginosa | 2 (0.7) | 0 (0.0) | 2 (1.3) | 0.212 |
| Escherichia coli | 9 (3.3) | 3 (2.5) | 6 (4.0) | 0.496 |
| Enterobacter cloacae | 1 (0.4) | 1 (0.8) | 0 (0.0) | 0.271 |
| Klebsiella pneumoniae | 3 (1.1) | 2 (1.7) | 1 (0.65) | 0.414 |
| Serratia marcescens | 4 (1.5) | 2 (1.7) | 2 (1.3) | 0.887 |
| Others | 5 (1.9) | 3 (2.5) | 2 (1.3) | 0.465 |
| Candida spp | 3 (1.1) | 3 (2.5) | 0 (0.0) | 0.051 |
| Erysipelothix rhusiopathiae | 1 (0.4) | 0 (0.0) | 1 (0.65) | 0.378 |
| Brevibacterium casei | 1 (0.4) | 0 (0.0) | 1 (0.65) | 0.378 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
